Abstract
COPD is a chronic disease, characterized by persistent airflow limitation and systemic manifestations. It is suggested that the adipose tissue may play a critical role in promoting systemic inflammation in COPD possibly by secretion of adipokines (including visfatin). Visfatin (visceral fat-derived hormone) is a pro-inflammatory cytokine which acts on early B-lineage precursor cells. It has also an enzyme activity (nicotinamide phosphoribosyltransferase): the rate-limiting enzyme in salvage pathway of NAD.
The aim of our study was to evaluate the role of visfatin as possible biomarker in COPD. We assessed the serum levels of visfatin in 58 patents with COPD and 22controls by commercial ELISA kit.
COPD patients had significantly higher visfatin levels compared to controls (181.04±13.82pg/ml vs. 74.4±14.13pg/ml, p<0.0001). In the group of patients the current smokers had significantly higher visfatin compared to non- or ex-smokers (p= 0.013), and the overweight patients had elevated concentrations than patients with normal BMI (219.46±20.86pg/ml vs. 147.80±29.49pg/ml, p=0.041).
Serum leptin was significantly higher in patients with stages GOLD III and IV than those stages GOLD I and II (221.3±17.85pg/ml vs. 159.86±18.11pg/ml, p=0.033); it tended to be higher in patients of group D compare to those of A and B (GOLD 2017) (p=0.078); and it positively correlated with the CAT test points (r=0.227, p=0.035).
According to our results visfatin is affected by smoking habits and might be used as biomarker for more advanced and symptomatic COPD.
This work was performed with the support of SUP 3/2017 and project 3/2018, Medical Faculty, Trakia University, Stara Zagora, Bulgaria.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA5408.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019